Top 5 Clean Energy Stocks To Watch Right Now

What is the side hustle?  Let’s put it this way.  NOT participating in this “dance” may cause some Millennials to have an identity crisis.  They are the generation of the 1099; the folks who have figured out how to get “side” jobs to fill in the money gaps created by the 2008 financial crisis.

The Urban Dictionary gives the best definition; A side hustle is a “Sideline that brings in cash; something other than your main job.  Maybe playing weekend gigs or life coaching.  SELLING AMWAY IS NOT A SIDE HUSTLE – it’s just a stupid way to alienate your friends.”

Did Millennials Invent This?

No. They were an underemployed generation, unfulfilled by serving ‘Grande Frothy Lattes’ instead of achieving their life’s dream of using their journalism degree to write articles for a prestigious magazine.

Top 5 Clean Energy Stocks To Watch Right Now: EP Energy Corporation(EPE)

Advisors’ Opinion:

  • [By Paul Ausick]

    EP Energy Corp. (NYSE: EPE) posted a new 52-week low of $1.85 Tuesday, down nearly 22% after closing at $2.37 on Monday. The 52-week high is $7.49. Volume was about 3.2 million, around 5 times the daily average of around 600,000. The oil and gas exploration and production firm has launched an exchange program extending the maturity date to 2024 on $1.2 billion in 9.375% notes due in 2020.

  • [By Andrew Efimoff]

    WTI crude oil plunged 3.11 percent on Friday to $48.99 a barrel. Below are the biggest energy losers for the day:

    California Resources Corporation (NYSE: CRC): -19.22%
    Dynamic Materials (NASDAQ: BOOM): -12.39%
    Clayton Williams Energy (NYSE: CWEI): -11.45%
    Dynergy (NYSE: DYN): -11.91%
    EP Energy Corporation (NYSE: EPE): -11.20%
    Mexco Energy (NYSE: MXC) -10.90%
    Whiting Petroleum (NYSE: WLL) -10.79%
    Southwestern Energy Company (NYSE: SWN) -10.79%
    SM Energy Company (NYSE: SM) -10.38%
    Real Goods Solar (NASDAQ: RGSE) -10.34%

    Posted-In: Commodities After-Hours Center Markets Movers

Top 5 Clean Energy Stocks To Watch Right Now: MannKind Corporation(MNKD)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Hopes were high for MannKind (MNKD) when its inhaled insulin Afrezza was approved by the FDA more than two years ago. At the time, Barron’s warned that it was time to dump MannKind’s shares, something that now seems prescient, as its shares have since tumbled 95%. No wonder, as the news since then has been far from good. MannKind found a partner in Sanofi (SNY), only to get dumped in early 2016, and has since been forced to sell property to raise cash. And now MannKind could be on the verge of being delisted from the Nasdaq due to its sub $1 stock price. What now? Piper Jaffray’sJoshua Schimmer and team see a reverse stock split in MannKind’s future:

    [MannKind] has been focused on relaunch of Afrezza (inhaled insulin) for diabetes since Sanofi terminated its partnership for that program last year. Progress has been slow as the company first deployed a contract sales force but is now switching to an internal one. Hiring is nearly complete and reps will be out in the field soon. The company has also made strides in expanding reimbursement coverage for Afrezza. MannKind is also in the process of launching a new Titration Pack for Afrezza that allows for greater dosing flexibility in an attempt to simplify prescribing patterns of the drug. However with all these efforts, scrips have not yet shown signs of life in a very crowded diabetes market where MannKind is likely to struggle to claim share of voice relative to large pharma competitors. MannKind held a special meeting of stockholders in February 2017 in order to gain authority for a reverse stock split, if necessary to avoid de-listing by NASDAQ. MannKind recently indicated its cash position to be at ~$120M (and added $17M from the sale of its Valencia facility in February), which does provide some room to grow Afrezza sales before having to seek out yet another dilutive raise. However, its unclear if any of the new commercial efforts will help to rescue Afrezza sales. Ou

  • [By Lisa Levin]

    MannKind Corporation (NASDAQ: MNKD) shares were also up, gaining 24 percent to $6.59. H.C. Wainwright initiated coverage on MannKind with a Buy rating and a $7.00 price target.

  • [By Lisa Levin]

    In trading on Tuesday, healthcare shares fell 0.48 percent. Meanwhile, top losers in the sector included MannKind Corporation (NASDAQ: MNKD), down 10 percent, and BioDelivery Sciences International, Inc. (NASDAQ: BDSI) down 10 percent.

  • [By James E. Brumley]

    When most investors think of diabetes stocks, names like Novo Nordisk A/S (ADR) (NYSE:NVO) and MannKind Corporation (NASDAQ:MNKD) come to mind. And well they should. Novo Nordisk is the biggest insulin company in the world, and while MannKind is relatively small, it’s a name that turns heads simply because it came up with an inhalable insulin that – after a slow start – is getting a little traction.

    In both cases though, the paradigm is the same one that was first used decades ago. That is, if a person isn’t making their own insulin, then it must be introduced externally. What if instead a diabetic’s glucose levels could be controlled by turning on the cells in their body responsible for processing that sugar? That’s the approach Cell MedX Corp (OTCMKTS:CMXC) is taking, using a relatively new but very compelling science.

    While chemical-based manufactured pharmaceuticals were largely the core of healthcare for well over the past century, it’s become clear that our bodies – right down to our cells – are also electrical in nature. Not only do they produce it, they need it to function properly. The FDA has even recently approved a therapeutic device that delivers mild electrical currents to and through an individual’s body as a means of treating pain. This “electromedicine” has also shown a certain degree of efficacy as a treatment for several illnesses, including cancer. Specifically, electrical currents have been demonstrated to force pleomorphic cancer microbes into hibernation, essentially making a cancerous cell a normal, healthy cell again. So, using an electrical current as a means of therapy for diabetics isn’t far-fetched at all. Indeed, it’s quite brilliant.

    As for how Cell MedX is using the idea, it’s actually quite simple. The device is called an eBalance. At first glance it just looks like another ordinary tablet computer. A closer inspection of the e-Balance device, however, makes it clear that it’s not just another tablet. It’

Top 5 Clean Energy Stocks To Watch Right Now: Apache Corporation(APA)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Cramer and the AAP team say Apache’s (APA) mixed results are a buying opportunity. Find out what they’re telling their investment club members with a free trial subscription to Action Alerts PLUS.

  • [By WWW.THESTREET.COM]

    Cramer and the Action Alerts PLUS team say they still believe in their embattled Permian names, Cimarex (XEC) and Apache (APA) , both of which have benefited from a slow rotation in recent weeks. These names can produce and profit here. Schlumberger (SLB) remains best in class and Magellan Midstream Partners just might be the best way to play oil given that the pipelines will be needed to transport the new wave of oil able to be drawn out of the ground from increasingly efficient American producers. Get in on the discussion by getting a free trial subscription to Action Alerts PLUS.

  • [By Lee Jackson]

    These companies also reported insider buying last week: Apache Corp. (NYSE: APA), Halliburton Co. (NYSE: HAL), Revlon Inc. (NYSE: REV), Valeant Pharmaceuticals International Inc. (NYSE: VRX) and U.S. Steel Corp. (NYSE: X).

  • [By WWW.THESTREET.COM]

    Cramer and Jack Mohr think Apache’s (APA) management has positioned the company for growth through both innovation and efficiency. Read what they are telling their investment club members with a free subscription to Action Alerts PLUS.

Top 5 Clean Energy Stocks To Watch Right Now: (LGEAF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    There are other areas of smartphone innovation pursued by other companies besides Apple. The development of OLED screens has been a significant innovation pursued mainly by Korean giants Samsung (OTC:SSNLF) and LG (OTC:LGEAF). It is now being reported that Samsung and LG will introduce smartphones with foldable OLED screens this year.

  • [By SEEKINGALPHA.COM]

    However, Apple is turning to LG (OTC:LGEAF) and the Herald reports that Apple is even considering investing in a future plant in China to build flexible displays. It’s thought that the bendable displays could be available as early as 2019.

  • [By SEEKINGALPHA.COM]

    The importance of cellular connectivity for wearables, particularly for smartwatches, has been a theme of mine since last year, and I’m glad to see other analysts and organizations starting to pick up on it. I’ve discussed Qualcomm’s (NASDAQ:QCOM) development of the Snapdragon Wear SOC that manufacturers are using for Android Wear 2 smartwatches with LTE connectivity, such as the LG Watch Sport (OTC:LGEAF). Such watches provide voice calling and cellular data connections and anticipate the future direction of the smartwatch.

Top 5 Clean Energy Stocks To Watch Right Now: Roche Holding AG (RHHBY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Only Roche (OTCQX:RHHBY) is producing a drug with a similar mechanism to Gilead’s GS-9620. Other drug manufacturers are focused on a variety of methods which could be supportive when used in combination with GS-9620. More information on the drug is expected to be released from Phase 2 clinical trial results in Q1’17. It’s important to note from AASLD abstracts (Abstract 1851) and earlier clinical trial results (page 11) that there is not much evidence of efficacy at this point in time.

  • [By SEEKINGALPHA.COM]

    As with INCY, the focus of Regeneron (NASDAQ:REGN) is cutting-edge science to produce superior molecules that have limited competition. Its flagship drug Eylea took on and defeated the incumbent, Lucentis from Roche (OTCQX:RHHBY), by having both a longer activity leading to less frequent injections into the eye and an additional mechanism of action. This provides it partial insulation from pricing pressures; and, REGN has never taken a price increase on Eylea, which has been on the market since late 2011. Eylea is now selling $5 B globally, a number that is rising and that I believe exceeds the pace set by Revlimid and almost every other drug in history (inflation not accounted for, though).

  • [By Ben Levisohn]

    We expect a strong 2017 performance from Keytruda in NSCLC, though revenue and EPS estimates are now 2%-7% and 5%-12% below consensus between 2017E-20E. We also expect further pressure on Keytruda in 2018, driven by share losses in first-line non-small cell lung cancer to Bristol-Myers Squibb (BMY), AstraZeneca (AZN) and Roche (RHHBY) as well as an increasing overhang from the Januvia/ Janumet patent expiries as they loom ever closer. Merck screens poorly on many valuation metrics to us and we have downgraded the shares to Underperform.

  • [By SEEKINGALPHA.COM]

    Source: Biogen’ Q2 2017 Results Presentation

    Tysabri sales were $496, in line with consensus. This dynamic has been helpful to reassure investors that the impact from the recent launch of Roches (OTCQX:RHHBY) Ocrevus has been limited and that the franchise could be still defended over the next 5 years.

  • [By WWW.THESTREET.COM]

    Novartis AG (NVS) said Monday that it has received approval from the European Commission for a blood cancer treatment known as Rixathon, a biosimilar version of Roche AG’s (RHHBY) blockbuster Rituxan that generated around $7.5 billion in sales last year. 

Leave a Reply

Your email address will not be published. Required fields are marked *